CCEL (Cryo-Cell International) Debt-to-EBITDA : (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CCEL Cryo-Cell International Inc CCEL
66 GF Score
Price $4.40
GF Value $5.41
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Cryo-Cell International Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Cryo-Cell International's Short-Term Debt & Capital Lease Obligation for the quarter that ended in May. 2026 was $0.62 Mil. Cryo-Cell International's Long-Term Debt & Capital Lease Obligation for the quarter that ended in May. 2026 was $8.34 Mil. Cryo-Cell International's annualized EBITDA for the quarter that ended in May. 2026 was $6.45 Mil. Cryo-Cell International's annualized Debt-to-EBITDA for the quarter that ended in May. 2026 was 1.39.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Cryo-Cell International's Debt-to-EBITDA or its related term are showing as below:

CCEL' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -7.88   Med: 1.52   Max: 12.01
Current: 12.01

During the past 13 years, the highest Debt-to-EBITDA Ratio of Cryo-Cell International was 12.01. The lowest was -7.88. And the median was 1.52.

CCEL's Debt-to-EBITDA is ranked worse than
92.74% of 482 companies
in the Healthcare Providers & Services industry
Industry Median: 2.2 vs CCEL: 12.01

Cryo-Cell International  (AMEX:CCEL) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Cryo-Cell International Debt-to-EBITDA Related Terms

Cryo-Cell International Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Cryo-Cell International's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cryo-Cell International Debt-to-EBITDA Chart

Cryo-Cell International Annual Data
Trend Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23 Nov24 Nov25
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cryo-Cell International Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

CCEL vs PIII, EHSI, DCGO: Debt-to-EBITDA Comparison

For the Medical Care Facilities subindustry, Cryo-Cell International's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cryo-Cell International Debt-to-EBITDA vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Cryo-Cell International's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Cryo-Cell International's Debt-to-EBITDA falls into.


CCEL
66GF Score
Cryo-Cell International Inc CCEL
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cryo-Cell International Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Cryo-Cell International's Debt-to-EBITDA for the fiscal year that ended in Nov. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.913871 + 8.644758) / 1.097221
=10.53

Cryo-Cell International's annualized Debt-to-EBITDA for the quarter that ended in May. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.617023 + 8.342694) / 6.452908
=1.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (May. 2026) EBITDA data.

Is Cryo-Cell International (CCEL) Overvalued in 2026?

Based on GuruFocus' analysis, Cryo-Cell International stock appears to be undervalued. The current stock price of $4.40 is trading 18.7% below its estimated GF Value™ of $5.41. GuruFocus considers Cryo-Cell International to be Modestly Undervalued.

Key valuation signals for CCEL:

  • Debt-to-EBITDA:
  • GF Value™: $5.41 vs. price of $4.40 (18.7% below fair value)
  • GF Score™: 66/100 with 6 warning signs

No single metric tells the full story. See the CCEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cryo-Cell International Business Description

Other Exchanges ZCY:Germany
Address 700 Brooker Creek Boulevard, Suite 1800, Oldsmar, FL, USA, 34677
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
66GF Score

Get the complete analysis for CCEL

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.40
Price
$5.41
GF Value